American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
Tuesday 29th October 2024
Explore key findings on Buprenorphine/Naloxone vs Methadone for opioid use disorder, plus insights on naloxone trends and more.
5 minutes
Informative
Educational
Supportive
Hopeful
Compassionate
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
144 (View all)
Do you want to link to this podcast?
Get the buttons here!Buprenorphine/Naloxone vs Methadone: Key Findings on Opioid Use Disorder Treatment
Episode Overview
- Methadone shows lower risk of treatment discontinuation compared to Buprenorphine/Naloxone.
- Both treatments have low mortality rates.
- GIP and GLP-1RA prescriptions are linked to lower rates of opioid overdose and alcohol intoxication.
- Layperson-administered naloxone has increased by 44%, highlighting the need for better education.
- Medications for opioid use disorder significantly reduce emergency department visits and inpatient admissions.
"The risk of treatment discontinuation was higher among recipients of buprenorphine/naloxone compared with methadone"
In this episode of 'This Week in Addiction Medicine from ASAM', the spotlight is on a compelling study comparing Buprenorphine/Naloxone and Methadone for treating opioid use disorder. The research, conducted by JAMA Network, dives into the effectiveness of these treatments in a population-based retrospective cohort study. With 30,891 individuals participating, the study found that while both treatments had low mortality rates, Methadone had a lower risk of treatment discontinuation compared to Buprenorphine/Naloxone (81.5% vs 88.8% within 24 months).
This is crucial information for anyone considering or currently undergoing treatment for opioid use disorder. The episode doesn't stop there. It also covers another fascinating study on the association between prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonists (GLP-1RA) with substance-related outcomes in patients with opioid and alcohol use disorders. The findings suggest that these prescriptions are linked to lower rates of opioid overdose and alcohol intoxication, offering hope for those managing multiple health issues.
Additionally, you'll hear about a study examining layperson-administered naloxone trends reported in emergency medical service activations. This study found that while naloxone administrations decreased by 6% between 2020 and 2022, layperson-administered naloxone increased by 44%, highlighting the importance of naloxone education and access.
Rounding out the episode is a discussion on the impact of medications for opioid use disorder on acute care utilisation in rural communities, a novel opioid withdrawal protocol in an emergency department setting, and tobacco product use among middle and high school students. Each segment provides valuable insights and practical information that can benefit both healthcare professionals and individuals affected by addiction. If you're looking for up-to-date research and practical advice on addiction medicine, this episode is a must-listen.
It offers a comprehensive overview of recent studies and their implications, making it an invaluable resource for anyone involved in addiction treatment or recovery.